Inflectis BioScience announced successful completion of Phase 1 clinical trial of IFB-088
Inflectis BioScience, one of the Remiges Ventures' portfolio companies announced today that it has completed its Phase 1 study for the firm's program IFB-008 successfully. IFB-088 is an oral small molecule targeting the stress-induced PPP1R15A/PP1c phosphatase complex. Results of this randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study (SAD/MAD) in 72 healthy volunteers demonstrated that administration of IFB-088 was safe and well tolerated. No serious adverse events, dose-limiting toxicities, or clinically significant abnormalities were observed. The pharmacokinetic parameters were consistent with data derived from extensive studies in animal models.
For more detailed information please visit the above web page